RxDoctor Payments Data

Barry Kessler, MD

Cardiology · Delray Beach, FLNPI 1093762445

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Johnson & Johnson at 28.5% of the total. Reporting peaked in 2023 at $542 and has fallen 62.0% since, to $206 in 2025.

$1,889in general payments, 2019–2025

Across 36 payments — averaging $52.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$539
  • Merck$222
  • Novartis$178
  • Boston Scientific$157
  • Atricure, Inc.$136
  • Pfizer$128
  • plus $529 from 7 others

What the payments were for

  • Food & beverage$1,86499%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,889 in reported general payments places this provider in the 65th percentile of 45 cardiology providers in Florida.

See all cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$186,379
Medicare patients
570
Services billed
2,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$136,030
XareltoRivaroxaban97$116,144
Repatha SureclickEvolocumab58$76,290
EntrestoSacubitril/Valsartan32$54,103
NexlizetBempedoic Acid/Ezetimibe19$22,444
NexletolBempedoic Acid19$18,193
VascepaIcosapent Ethyl19$16,702
BrilintaTicagrelor12$10,227
Rosuvastatin Calcium355$4,340
Metoprolol Succinate262$4,244
Ranolazine ErRanolazine24$2,510
Ezetimibe105$2,294
Atorvastatin Calcium184$1,509
Bisoprolol Fumarate71$1,248
Losartan Potassium109$1,203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$128$136,030108 claims
Johnson & JohnsonXarelto$539$116,14497 claims
NovartisEntresto$178$54,10332 claims
AstraZenecaBrilinta$14$10,22712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 45 cardiology providers in Florida.

Other cardiology in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →